Japanese warnings for fingolimod revised on cardiac safety concerns
This article was originally published in Scrip
Executive Summary
Japan's ministry of health, labour and welfare has ordered revisions to the warnings and basic precautions for the multiple sclerosis drug fingolimod after reviewing reports of cardiac problems in other markets.